Contineum Therapeutics Reports Third-Quarter 2026 Financial Results
Business Wire•03/11/2026•16:05 ET
0
Key Highlights
- ➤Cash, cash equivalents and marketable securities $244.5 million as of September 30, 2026
- ➤Cash runway projected through mid-2029, funding planned operations
- ➤Net loss $18.7 million versus $12.8 million in third-quarter 2025
- ➤Research and development expenses $16.0 million, up 45 percent year over year
- ➤PROPEL-IPF expanded to over 100 sites across 16 countries
Expert Statements
Carmine Stengone, CEO of Contineum Therapeutics
“Lysophosphatidic acid 1 receptor (LPAR1) antagonism as a treatment approach for pulmonary fibrosis has exceptionally strong clinical validation with multiple trials successfully completed including more than 1,600 patients.”
Carmine Stengone, CEO of Contineum Therapeutics
“We believe the LPAR1 class can be the ideal backbone for combination treatments.”
Carmine Stengone, CEO of Contineum Therapeutics
“Our LPAR1 antagonist, PIPE-791, is potentially differentiated in key ways including a favorable safety and tolerability profile, sustained target engagement which we believe has the potential for improved efficacy, and superior convenience in a one-time daily, low oral dose with no titration required for patients.”
Carmine Stengone, CEO of Contineum Therapeutics
“We continue to expand our footprint for PROPEL-IPF, with over 100 sites now online in 16 countries to facilitate a steady pace of enrollment.”
Carmine Stengone, CEO of Contineum Therapeutics
“With a projected cash runway that extends through mid-2029, we are well positioned with capital resources one year past the estimated completion of our idiopathic pulmonary fibrosis (IPF) trial.”
Contineum Therapeutics Reports Third-Quarter 2026 Financial Results
Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for inflammatory and fibrotic diseases with significant unmet need, today reported its third-quarter 2026 financial results.
Get started
Create a free account to read the full story.